Nvidia slides further in post-market trading after plunge that wiped out almost $300 billion in market cap

Nvidia slides further in post-market trading after plunge that wiped out almost 0 billion in market cap


Nvidia CEO Jensen Huang speaks during Computex 2024 in Taipei on June 4, 2024. 

I-hwa Cheng | AFP | Getty Images

Nvidia shares fell 2% in extended trading after Bloomberg reported that the company received a subpoena from the Department of Justice as part of an antitrust investigation.

The slide comes after Nvidia dropped nearly 10% during regular trading, wiping $279 billion off its market cap.

The DOJ probe has not reached the stage of a formal complaint, according to Bloomberg, and the agency is asking questions about whether Nvidia makes it harder to switch to other suppliers of AI chips. Nvidia has over 80% of the market for data center AI chips, according to industry estimates.

Nvidia’s huge rise in recent years has been directly tied to its dominance in AI chips for data centers, established years before competitors AMD and Intel started taking the category seriously. Nearly a decade ago, Nvidia developed a programming language for its chips, called CUDA, which is a key tool for engineers who train advanced AI models like the one at the heart of ChatGPT.

Many of Nvidia’s top customers are cloud companies as well as internet giants, including Microsoft, Alphabet, Meta, Amazon, and Tesla.

As Nvidia’s AI chips have become a hot commodity, the company has released new enterprise software subscriptions and marketed its networking products as important compliments to get the most out of its chips.

Recent versions of Nvidia’s chips can come pre-installed in entire Nvidia-designed server racks, an example of Nvidia’s effort to move from being a mere parts supplier to an entire systems provider.

Representatives from Nvidia and the DOJ declined to comment to CNBC.



Source

Revolution Medicines’ potential breakthrough pancreatic cancer drug succeeds in late-stage trial
World

Revolution Medicines’ potential breakthrough pancreatic cancer drug succeeds in late-stage trial

Pancreatic cancer, illustration Nemes Laszl | Science Photo Library | Getty Images Revolution Medicines‘ drug for pancreatic cancer succeeded in a highly anticipated Phase 3 trial, almost doubling the typical length of survival and slashing the risk of death by 60% versus chemotherapy, the company said Monday. RevMed said its daily pill, daraxonrasib, met all […]

Read More
UK ‘not supporting’ U.S. Iran blockade as France’s Macron confirms ‘multinational’ talks on the Strait of Hormuz
World

UK ‘not supporting’ U.S. Iran blockade as France’s Macron confirms ‘multinational’ talks on the Strait of Hormuz

U.S. President Donald Trump and British Prime Minister Keir Starmer hold a press conference following their meeting at Chequers, near Aylesbury, Britain, Sept. 18, 2025. Kevin Lamarque | Reuters The U.K. is “not supporting” the U.S. blockade of Iranian ports, Prime Minister Keir Starmer said on Monday, insisting that the country would not get “dragged […]

Read More
Treasury yields rise as collapse of Iran talks clouds inflation outlook
World

Treasury yields rise as collapse of Iran talks clouds inflation outlook

Treasury yields edged higher on Monday as the breakdown of negotiations between Iran and the U.S. clouded the inflation outlook once again. The yield on the 10-year U.S. Treasury note — the benchmark for government borrowing — was up more than 1 basis point at 4.333%. The 2-year Treasury note yield, which is more sensitive to short-term Federal Reserve interest rate […]

Read More